No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
IPSEY IPSEN SA SPONS ADR EA REPR 0.25 ORD
- 27.310
- -0.815-2.90%
15min DelayClose Dec 24 13:00 ET
9.04BMarket Cap12.88P/E (TTM)
27.310High27.310Low657Volume27.310Open28.125Pre Close17.94KTurnover0.00%Turnover Ratio13.59P/E (Static)330.85MShares33.97052wk High2.28P/B9.04BFloat Cap27.11052wk Low0.32Dividend TTM330.85MShs Float33.970Historical High1.18%Div YieldTTM0.00%Amplitude27.110Historical Low27.310Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Eton Pharmaceuticals Enters Asset Purchase Agreement To Acquire Increlex (Mecasermin Injection) From Ipsen; No Terms Disclosed
Gilead Wins FDA Nod for Liver Disease Drug
Gilead Exits J&J Royalty Deal for Liver Drug Ahead of Potential FDA Nod
IPSEN - Buy-back Programme - Art 5 of MAR - Week 30 - 2024
Ipsen Liver Disease Drugs Endorsed in EU
Ipsen And Day One Earlier Announced Exclusive Ex U.S. Licensing Agreement To Commercialize Tovorafenib For The Most Common Childhood Brain Tumor
Heat List
US
Overall
Symbol
Price
% Chg
No Data